[Clinical course of COVID-19 in the Netherlands: an overview of 2607 patients in hospital during the first wave].

Klinisch beloop van covid-19 in Nederland.

Journal

Nederlands tijdschrift voor geneeskunde
ISSN: 1876-8784
Titre abrégé: Ned Tijdschr Geneeskd
Pays: Netherlands
ID NLM: 0400770

Informations de publication

Date de publication:
11 01 2021
Historique:
entrez: 2 3 2021
pubmed: 3 3 2021
medline: 13 3 2021
Statut: epublish

Résumé

To systematically collect clinical data from patients with a proven COVID-19 infection in the Netherlands. Data from 2579 patients with COVID-19 admitted to 10 Dutch centers in the period February to July 2020 are described. The clinical data are based on the WHO COVID case record form (CRF) and supplemented with patient characteristics of which recently an association disease severity has been reported. Survival analyses were performed as primary statistical analysis. These Kaplan-Meier curves for time to (early) death (3 weeks) have been determined for pre-morbid patient characteristics and clinical, radiological and laboratory data at hospital admission. Total in-hospital mortality after 3 weeks was 22.2% (95% CI: 20.7% - 23.9%), hospital mortality within 21 days was significantly higher for elderly patients (> 70 years; 35, 0% (95% CI: 32.4% - 37.8%) and patients who died during the 21 days and were admitted to the intensive care (36.5% (95% CI: 32.1% - 41.3%)). Apart from that, in this Dutch population we also see a risk of early death in patients with co-morbidities (such as chronic neurological, nephrological and cardiac disorders and hypertension), and in patients with more home medication and / or with increased urea and creatinine levels. Early death due to a COVID-19 infection in the Netherlands appears to be associated with demographic variables (e.g. age), comorbidity (e.g. cardiovascular disease) but also disease char-acteristics at admission.

Identifiants

pubmed: 33651497
pii:

Types de publication

Journal Article

Langues

dut

Sous-ensembles de citation

IM

Auteurs

Joop P van den Bergh (JP)

VieCuri Medisch Centrum.

Martijn Beudel (M)

Amsterdam UMC.
Contact: Martijn Beudel (m.beudel@amsterdamumc.nl).

Wim Boersma (W)

Noordwest Ziekenhuisgroep.

Tom Dormans (T)

Zuyderland Ziekenhuis.

Renee A Douma (RA)

Flevoziekenhuis.

Annet Eerens (A)

Treant Zorggroep.

Lucas M Fleuren (LM)

Amsterdam UMC.

Lianne de Haan (L)

Flevoziekenhuis.

Shi Hu (S)

Universiteit van Amsterdam.

Deborah Hubers (D)

Universiteit Twente.

Martijn de Kruif (M)

Zuyderland Ziekenhuis.

Pieter L Kubben (PL)

Maastricht UMC.

Peter G Noordzij (PG)

St Antonius Ziekenhuis.

Maarten Ottenhoff (M)

Maastricht UMC.

Auke C Reidinga (AC)

Martini Ziekenhuis.

Roos S C Renckens (RSC)

Noordwest Ziekenhuisgroep.

Sander Rigter (S)

St Antonius Ziekenhuis.

Daisy Rusch (D)

Martini Ziekenhuis/UMCG.

Michiel Schinkel (M)

Amsterdam UMC.

Suat Simsek (S)

Noordwest Ziekenhuisgroep.

Patricia Stassen (P)

Maastricht UMC.

Robert Stassen (R)

Zuyderland Ziekenhuis.

Rajat M Thomas (RM)

Amsterdam UMC.

Max Welling (M)

Universiteit van Amsterdam.

Caroline E Wyers (CE)

VieCuri Medisch Centrum.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH